FDA Approves First Triple-Combination Diabetes Pill: Metformin, SGLT2 Inhibitor, and DPP-4 in One Tablet

Why Is a Triple-Combination Diabetes Pill Important for Patients?

Medication non-adherence remains one of the greatest challenges in type 2 diabetes management. A widely cited meta-analysis published in Diabetes Care found that adherence to oral diabetes medications ranges from approximately 36% to 93%, with many real-world studies reporting rates around 50–60%. The complexity of multi-pill regimens is a key contributor: research consistently shows that reducing pill burden improves adherence. A 2016 systematic review in Current Medical Research and Opinion found that fixed-dose combination therapies are associated with significantly better adherence compared to free-drug combinations. This triple-combination tablet addresses this by combining three complementary mechanisms of action — insulin sensitization (metformin), urinary glucose excretion (bexagliflozin, an SGLT2 inhibitor), and incretin enhancement (sitagliptin, a DPP-4 inhibitor) — into a single tablet.

Clinical trials supporting the approval compared the fixed-dose triple combination to dual-therapy regimens. Results showed that significantly more patients on the triple combination achieved HbA1c below 7% compared to those on dual therapy. Adherence monitoring demonstrated substantially higher pill-taking consistency among patients on the single-tablet regimen compared to those taking three separate medications. The American Diabetes Association has long recommended simplifying medication regimens when possible, and this approval represents a step forward in that effort. Bexagliflozin itself received FDA approval in January 2023 as a standalone SGLT2 inhibitor (marketed as Brenzavvy), and sitagliptin (Januvia) has been available since 2006.

What Are the Clinical Benefits Beyond Blood Sugar Control?

The SGLT2 inhibitor component (bexagliflozin) contributes cardiorenal benefits beyond glycemic control. Landmark trials of SGLT2 inhibitors — including EMPA-REG OUTCOME (empagliflozin), DECLARE-TIMI 58 (dapagliflozin), and CREDENCE (canagliflozin) — have consistently shown that this drug class reduces the risk of heart failure hospitalization and slows progression of chronic kidney disease. SGLT2 inhibitors typically produce weight loss of 2–3 kg and systolic blood pressure reductions of 3–5 mmHg compared to placebo. They also reduce urinary albumin excretion, suggesting nephroprotective effects. Current ADA Standards of Care recommend SGLT2 inhibitors for patients with type 2 diabetes who have or are at risk for cardiovascular disease or chronic kidney disease.

The safety profile of the triple combination is expected to be consistent with the known profiles of each individual component. Common adverse effects associated with this drug combination include genital mycotic infections (a well-known SGLT2 inhibitor side effect occurring in approximately 5–10% of patients), gastrointestinal complaints primarily from metformin, and a low risk of hypoglycemia since none of the three components directly stimulate insulin secretion. Patients should be monitored for rare but serious risks including diabetic ketoacidosis (associated with SGLT2 inhibitors) and lactic acidosis (associated with metformin in patients with significant renal impairment). The combination is not recommended for patients with an estimated GFR below 30 mL/min/1.73 m².